published online in Lancet Neurology, researchers from the Karolinska Institute gave 58 men and women with mild-to-moderate Alzheimer’s disease injections of CAD106 or a placebo and followed them for three years. Three-quarters of those who received CAD106 developed antibodies against beta amyloid protein. Virtually all of them—including those getting the placebo—reported one or more side effects, ranging from inflammation of the nose and throat to headache, muscle pain, and fatigue.
None, though, developed meningoencephalitis, an inflammation of brain tissue. That’s important because a trial of an earlier vaccine called AN1792 was abruptly stopped when 6% of those getting the vaccine developed meningoencephalitis. That vaccine apparently triggered a response among certain white blood cells that wound up attacking healthy brain tissue.
Early steps toward an Alzheimer's vaccine - Harvard Health Publications